Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples